1185 Avenue of the Americas
3rd Floor
New York, NY 10036
United States
973 242 0005
https://www.synaptogen.com
Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 5
Nome | Titolo | Retribuzione | Esercitate | Anno di nascita |
---|---|---|---|---|
Dr. Alan J. Tuchman M.D., MBA(FAAN) | CEO & Director | 303,35k | N/D | 1947 |
Dr. Daniel L. Alkon M.D. | President, Chief Scientific Officer & Director | 375k | N/D | 1942 |
Mr. Robert Weinstein | CFO, Executive VP, Treasurer & Secretary | 568,92k | N/D | 1960 |
Synaptogenix, Inc. operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. The company focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer's disease. It also evaluates therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease. The company was incorporated in 2012 and is headquartered in New York, New York.
L'ISS Governance QualityScore di Synaptogenix, Inc. al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.